HYPERHOMOCYSTEINEMIA, ENDOTHELIAL DYSFUNCTION AND THEIR RELATION TO SEX STEROIDS IN POLYCYSTIC OVARY SYNDROME

The aim of our research was to estimate the relationship of levels testosterone, estradiol and levels of homocysteine and endothelin-1 at young women with polycystic ovary syndrome (PCOS). Methods. We examined 80 women (age 26.3±0.2 years, body mass index 23.3±0.9 kg/m2). Patients complained of primary infertility, menstrual dysfunction, hirsutism, acne. The control group: 20 healthy women. For the determination of the hormonal status, basal levels luteinizing hormone (LH), follicle stimulating hormone (FSH), total testosterone (T), estradiol (E2), sex-hormone binding globulin, antiMullerian hormone (AMH), homocysteine (Hcy), endothelin-1 were studied in serum. Monitoring of folliculogenesis was carried out. Statistical analysis of the data was performed using the statistical package settlement Microsoft Excel and Statistica 6.0. Results. On the basis of the increase of T, AMH, coefficient of LH/FSH, ovarian volume, number of antral follicles and the decrease of level of E2 was set diagnosis of PCOS. Hyperhomocysteinemia was found at 52.5% and the increase of endothelin-1 at 80% patients. The high levels of endothelin-1 was found significantly more frequent in the group women with hyperhomocysteinemia. There is a direct correlation between endothelin-1, testosterone-estradiol ratio and negative correlation with the level of estradiol at women with PCOS. Conclusions. The young patients with PCOS have a higher risk development of hyperhomocysteinemia, which combined with hyperandrogenemia and hypoestrogenemia leads to increased level of endothelin-1.

1. Bagos P.G. MTHFR C677T polymorphisms in PCOS: a meta-analysis. Mol. Hum. Reprod. 2009; 15 (1): 19-26.

2. Battaglia C. Mancini F., Cianciosi A. et al. Vascular risk in young women with polycystic ovary and polycystic ovary syndrome. Obstet. Gynecol. 2008; 111 (2Pt1): 385-95.

3. Blann A. Soluble markers of endothelial cell function. J. Clin. Haemorhol. Microcirc. 1997; 17 (1): 3-11.

4. Byractar F., Dereli D., Ozgen A.G. et al. Plasma homocysteine levels in polycystic ovary syndrome and congenital adrenal hyperplasia. Endocrin. J. 2004; 51 (6): 601-08.

5. Creamer D., Sullivan D., Bicknell R., Barker J. Angiogenesis in psoriasis. Angiogenesis. 2002; 5 (1): 231-36.

6. Ghoreschi K. Immunopathogenesis of psoriasis. J. Dtsch. Dermatol. Ges. 2003; 1 (7): 524-32.

7. Hahler B. An overview of dermatological conditions commonly associated with the obese patient. Ostomy Wound Manage. 2006; 52 (6): 34-36.

8. Inoue A., Yanagisawa M., Kimura S. The Human endothelin family: three structurally and pharmacologically distinet isopeptides predicted by three separate genes. Proc. Nat. Acad. Sci. 1989; 86: 2863-67.

9. Janagisawa M., Kunihara H., Tomobe S.J. Anovel potent vasoconstrictor peptide prodused by vascular endothelial cells. Nature. 1988; 332: 411-15.

10. John E. Deanfield, Julian P. Halcox, Ton J. Rabelink. Endothelial Function and Dysfunction. Contemporary Reviews in Cardiovascular Medicine. 2007; 115: 1285-95.

11. Kilic-Okman T., Guldiken S., Kucuk M. Relationship between homocysteine and insulin resistance in women with polycystic ovary syndrome. Endocr J. 2004; 51 (5): 505-08.

12. Kuroda K., Sapadin A., Shoji T. et al. Altered expression of angiopoietins and Tie2 endothelium receptor in psoriasis. J. Invest. Dermatol. 2001; 116 (6): 713-20.

13. Mallbris L., Ritchlin C., Stаhle M. Metabolic disorders in patients with psoriasis and psoriatic arthritis. Curr. Rheumatol. Reports Iss. 2006; 8 (5): 520-26.

14. Nickoloff B. J., Nestle F. О. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J. Clin. Invest. 2004; 113 (16): 1664-75.

15. Sills E.S., Genton M.G., Perloeet M. et al. Plasma homocysteine, fasting insulin, and androgen patterns among women with polycystic ovaries and in fertility. J. Obstet. Gynecol. Res. 2001; 27 (3): 163-68.

16. Sochorova R., Sinka L., Svecova D. et al. Endothelial cells in the blood in psoriasis. Bratisl. Lek. Listy. 2000; 101 (9): 529-30. 17. Sochorova R., Svecova D., Sinka L. Increased endothelemia as an indirect marker of changes in the blood vessel endothelium in psoriasis. J. Eur. Acad. Dermatol. Venereol. 2004; 18 (5): 556-59.

17. The Rotterdam ESHRE/ASRM- sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteriaand long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod. 2004; 19 (1): 41-47.

18. Ucak S., Ekmekci Tr., Basat O. et al. Comparison of various insulin sensivity indices in psoriatic patients and their relationship with type of psoriasis. J. Eur. Acad. Dermatol. & Venereol. 2006; 20 (5): 517-22.

19. Vanselow J., Pohland R., Furbass R. Promoter-2-derived Cyp19 expression in bovine granulosa cells coincides with gene-specific DNA hypo-methylation. Mol. Cell. Endocrinol. 2005; 233: 57-64.

20. Vitvitsky V., Prudova A., Stabler S. et al. Testosterone regulation of renal cystathionine betasynthase: implications for sex-dependent differences in plasma homocysteine levels. Am. J. Physiol. Renal. Physiol. 2007; 293 (2): 594-600.

21. Yildiz L., Akcay F., Aktas A. et al. Increased concentrations of plasma endothelin-1 and fibronectin in psoriasis. Acta Derm. Venereol. 1997; 77 (2): 166-67.

22. Yilmaz M., Biri A., Bukan N. et al. Levels of lipoprotein and homocystein in non-obese and obese patients with polycystic ovary syndrome. Gynecol. Endocrinol. 2005; 20 (5): 258-63.

23. Zhu B. T. On the mechanism of homocysteine pathophysiology and pathogenesis: a unifying. Histol. Histopathol. 2002; 17: 1283-91.